Invion

Invion Property, Plant & Equipment

The Property, Plant & Equipment (PP&E) of Invion (IVX.AX) as of Oct 30, 2026 is 58,483.00 AUD. In the previous year, Property, Plant & Equipment (PP&E) was 479.00 AUD — a change of 12,109.39% (higher).

Property, Plant & Equipment

58,483.00AUD

YoY

12,109.39%

Last updated:

Property, Plant & Equipment (PP&E) of Invion is 2023 58,483.00 AUD. Property, Plant & Equipment (PP&E) of Invion was 2022 479.00 AUD. It decreases by 12,109.39% higher compared to the previous year.

The Invion Property, Plant & Equipment history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Property, Plant & Equipment
Date
Property, Plant & Equipment
Jan 1, 2016
5,782.00 AUD
Jan 1, 2017
2,638.00 AUD
Jan 1, 2018
0.00 AUD
Jan 1, 2019
4,819.00 AUD
Jan 1, 2020
3,891.00 AUD
Jan 1, 2021
1,024.00 AUD
Jan 1, 2022
479.00 AUD
Jan 1, 2023
58,483.00 AUD
The Invion Property, Plant & Equipment history
YEARProperty, Plant & EquipmentYoY
58,483.00AUD+12,109.39%
479.00AUD-53.22%
1,024.00AUD-73.68%
3,891.00AUD-19.26%
4,819.00AUD—
0.00AUD-100.00%
2,638.00AUD-54.38%
5,782.00AUD-78.36%
26,723.00AUD-7.85%
29,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Property, Plant & Equipment (PP&E) of Invion is 58,483.00 AUD in 2023.

Property, Plant & Equipment (PP&E) of Invion changed from 479.00 AUD to 58,483.00 AUD, representing a 12,109.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Property, Plant & Equipment (PP&E) Invion since 2006 – with annual values, charts, and detailed analysis.

PP&E represents the physical assets used in operations, such as buildings, machinery, and equipment. It is the backbone of manufacturing and service delivery.

Property, Plant & Equipment (PP&E)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Property, Plant & Equipment (PP&E)'s Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Invion

All Key Metrics — Invion